you have unintentionally made it seem like this piece, critical of the rasagiline trial results, was a research study from the New England Journal of Medicine.
In fact, the ORIGINAL STUDY is what was published in the New England Journal of Medicine. Olanow et al published the actual study in the NEJM and from what I've read Olanow is cautiously excited about the results of the study.
http://www.pharmatimes.com/ClinicalN....aspx?id=16640
"The finding that early treatment with rasagiline 1mg per day provides benefits that cannot be achieved with later administration of the same drug indicates that these benefits are not simply due to a symptomatic effect of the drug and are consistent with the possibility that the drug is disease-modifying,” Dr Olanow commented.
“If this can be confirmed, this would be the first drug determined to have a disease-modifying effect in PD, and that is exciting news for the PD community.”
Your piece in the original post is NOT written by Olanow and was NOT published in the New England Journal of Medicine.
I don't know who wrote it, because I can't get the link to work, but it sounds like someone disgruntled and with an axe to grind.
Cal
------------------------------------------------------------------------------------
Quote:
Originally Posted by imark3000
I dont know whom to believe !
Imad
THE EFFECT OF RASAGILINE ON PARKINSON'S DISEASE
New England Journal of Medicine [2009] 361 (13) : 1268-1278 (Olanow CW, et al) Complete abstract
Claims based on the results of a recent clinical trial that Rasagiline (Azilect) slows the progression of Parkinson's Disease are not supported at all by that study's results. Yet it has still been very widely, and falsely claimed that Rasagiline slows the progression of Parkinson's Disease. Rasagiline is a MAO inhibitor, which is a type of drug that is often used in Parkinson's Disease alone, or alongside other treatments. For more information go to Rasagiline. The clinical trial involved over a thousand patients. In early-start treatment with Rasagiline at a dose of 1 mg per day, there was actually a worsening of Parkinson's Disease symptoms throughout the clinical trial. As time progressed during the clinical trial, the effect of 1mg of 1mg Rasagiline was found to be no different from those people that had taken Rasagiline for only half of the time. The use of 2mg Rasagiline per day was also shown to be no better than the use of 1mg or delaying the use of Rasagiline. For more current news go to Parkinson's Disease News. |